Philip Astley-Sparke
Executive ChairmanMr. Philip Astley-Sparke, F.S.A, is Director of Mestag Therapeutics Ltd from October 2026. Mr. Astley-Sparke is Independent Non-Executive Director of enGene Therapeutics Inc. (formerly known as enGene Holdings Inc.) from July 8, 2025. He has served on numerous public and private boards and is currently Chairman of Synox Therapeutics Ltd. He serves as Venture Partner at Forbion Capital Partners B.V. Mr. Astley-Sparke served as an Operating Partner of Forbion Capital Partners B.V. from 2024. He joined the Forbion Capital Partners B.V. in May 2012. He focuses on Biotechnology. He was Venture Partner of Forbion Capital Partners B.V. from May 2012 to 2024. He serves as Executive Chairman at Replimune Group, Inc. since April 01, 2024. He focuses on Biotechnology. He serves as an Independent Non-Executive Director of Forbion European Acquisition Corp. He had been the Independent Non-Executive Chairman of uniQure N. V. since September 22, 2016, until June 17, 2021 and its Independent Non-Executive Director since June 15, 2015 until June 17, 2021. He is a Co-Founder of Replimune Group, Inc. and served as its Executive Chairman since 2015 until April 2, 2020. Mr. Astley-Sparke was Secretary and Treasurer at Replimune Group, Inc. He is the Chief Executive Officer at Replimune Group, Inc. since January 2020 and has been its Director since 2015 and also served as its Interim Chief Financial Officer. All board and management affiliations mentioned below are current or past Forbion portfolio companies. He has extensive experience developing biotechnology companies from the research stage to pre-launch, as well as experience in commercial planning, including setting up commercial scale manufacturing. Mr. Astley-Sparke served as the President of US Operations at uniQure N. V. since January 2013 until February 2015. He provided strategic leadership and helped build uniQure's clinical, regulatory and commercial infrastructure in the United States. He served as a Vice President and General Manager at Amgen, Inc. until December 2011. He served as Executive at JPMorgan Chase & Co. He served as the President of BioVex, Inc. since July 2005, Chief Executive Officer since 2005 and its Chief Financial Officer since 2000. He successfully implemented exit strategy when the firm was being acquired by Amgen. In 2005, he established Biovex’ US operations from scratch, recruiting the entire US senior management team (outside the CTO) whilst setting up all key functions including commercial capabilities. He grew the Company to 70 employees in Woburn, MA while retaining 30 in Abingdon, UK. He served as an Investment Banker of JP Morgan H&Q (Robert Fleming), where he advised on several high-profile mergers and public financings. Over the years, he executed five major equity financings involving blue chip international Investor syndicates including the second largest biotech VC raise of 2009. He also oversaw the building of a launch grade manufacturing facility to zero default timelines and led his team through the agreement of a SPA with the FDA on the design of a pivotal study which commenced and was recruited on projected timeframes. Philip also served as the Chairman of Oxyrane from 2011 to 2020 and served on the board of Forbion acquisition Corp. After BioVex/Amgen, Philip was President at uniQure where he established their US infrastructure and served as the Company’s Chairman between 2016-2021. Mr. Astley-Sparke serves as the Non-Executive Chairman of Oxyrane UK Limited. He served as Member of Supervisory Board at uniQure N. V. since June 10, 2015 until June 15, 2016. He served as Chairman of BioVex Inc from November 2009 to March 2011. He served as a Director of BioVex, Inc. since 2000. He qualified as a Chartered Accountant with Arthur Andersen and holds FSA. He holds a B.Sc. in Cellular Pathology and Molecular Pathology from Bristol University (UK).
Positions
- Company NameReplimune Group, Inc.Stock CodeREPLPositionExecutive Chairman
